NC1 is a novel highly active allosteric inhibitor of protein tyrosine phosphatase, non-receptor type 22 (PTPN22) which is a lymphoid-specific tyrosine phosphatase (LYP).

ZINC194100678 is an effective PAK1 inhibitor with IC50 of 8.37μM. ZINC194100678 showed strong anti-proliferation activity, with IC50 value of 40.16μM against MDA-MB-231.

ZINC12409120 (R-4584) is a selective ERK inhibitor.ZINC12409120 inhibits ERK with an IC50 of 5.0 μM.ZINC12409120 inhibits ERK activity by interfering with FGF23:α-Klotho interaction.

UNC10217938A HCl (UNC7938 HCl) is a 3-deazapteridine analog. UNC10217938A HCl exhibits strong oligonucleotide enhancing effects. UNC10217938A HCl can modulate their intracellular trafficking and release from endosomes, leading to enhance oligonucleotides effects. UNC10217938A HCl also enhances the effects of siRNA and antisense oligonucleotides.

(S)-Desmethyl-NNC112 ((+)-Desmethyl-NNC112) is a selective PET radioligand that binds to D-dopamine receptors.

UNC1999 is a orally bioavailable, effective and specific inhibitor of EZH2 (IC50=2 nM) and EZH1 (IC50=45).

ZINC13466751 is a potent HIF-1α/von Hippel-Lindau interaction inhibitor(IC50 of 2.0 µM).

NC1153 is a blocker of IL-2-induced activation of JAK3 and its downstream substrates STAT5a/b. It promotes long-term allograft survival and sparing the recipient from multiple toxicities.

BNC105P is a benzofuran-based vascular disrupting agent (VDA) prodrug with potential anti-vascular and antineoplastic activities. Upon administration vascular disrupting agent BNC105P, the disodium phosphate ester of BNC105, is rapidly converted to BNC105; in activated endothelial cells, BNC105 binds to tubulin and inhibits its polymerization, which may result in a blockage of mitotic spindle formation, cell cycle arrest, and disruption of the tumor vasculature. Hypoxic conditions ensue, depriving tumor cells of nutrients and resulting in tumor cell apoptosis. In addition to its VDA activity, this agent has a direct cytotoxic effect on tumor cells by inhibiting tubulin polymerization. BNC105 is not a substrate for the multidrug-resistance P-glycoprotein (Pgp) transporter.

UNC10112785 is a novel potent inhibitor of CDK8, CDK19, and CDK9 with IC50 at 1.05, 2.67, and 19.9 nM, respectively, causing MYC loss through both transcriptional and posttranslational mechanisms, and suppressing PDAC anchorage-dependent and anchorage-independent growth, inducing the substantial loss of MYC protein in both two-dimensional (2D) and 3D cell cultures.

UNC10217938A is a 3-deazapteridine analog, has strong oligonucleotide enhancing effects.

UNC10201652 is a potent inhibitor of L1-specific intestinal bacterial β-glucuronidases (GUSs) and is able to act on Escherichia coli (E. coli) (IC50: 0.117 μM). glucuronide processing.

NC182 is a topo II inhibitor that shows selective and potent topo II inhibition on the induction of topo II-dependent DNA fragmentation.

BNC105 is a tubulin polymerization inhibitor. It has potent antiproliferative and tumor vascular disrupting properties.

NC190 is an inhibitor of topoisomerase II that inhibited the growth of FM3A cells in clinical trials. NC-190 strongly inhibited the growth of FM3A cells when cultured with NC-190 for 48 h (IC50: 0.019 μg/ml). NC-190 potently suppressed DNA synthesis with

UNC1215, an effective and specific MBT (malignant brain tumor) antagonist, binds L3MBTL3 (IC50/Kd: 40/120 nM). The selectivity of UNC1215 for L3MBTL3 is 50-fold higher versus other members of the human MBT family.

ZINC17167211 is a selective peroxisome proliferator-activated receptors-α agonist.

UNC1666 is a dual ATP-competitive small molecule tyrosine kinase inhibitor, which potently diminishes Mer and Flt3 phosphorylation in AML.

ONC1-13B is a potent androgen receptor (AR) antagonist with an ic50 in the range of 59-80 nM that inhibits PSA production in androgen-sensitive human PCa LNCaP cells.

UNC1079 is an selective L3MBTL3 domain inhibitor